C

Central Alabama Research | Birmingham, AL

Research site
(Unclaimed)
Location
10 Old Montgomery Highway, Suite 100, Birmingham, Alabama, United States of America

Site insights

Top conditions

Top treatments

Metformin
Triglyceride
Tanezumab
K-877
Obicetrapib
Bococizumab
casirivimab+imdevimab
Semaglutide
Panitumumab
Polypill

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 36 total trials
Locations recently updated

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will stu...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Rituximab
Drug: Lenalidomide

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with I...

Enrolling
Non-small Cell Lung Cancer
Drug: Pembrolizumab (MK-3475) 200 mg
Device: NovoTTF-200T

The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, c...

Active, not recruiting
Nonsmall Cell Lung Cancer
NSCLC
Drug: Immune checkpoint inhibitors or docetaxel
Device: NovoTTF-200T
Locations recently updated

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of MK-0616, an oral proprotein convertase subtilisin/kexin type 9...

Enrolling
Arteriosclerosis
Hypercholesterolaemia
Drug: Placebo
Drug: MK-0616

The purpose of the study is to confirm the safety and effectiveness of SB-01 For Injection in adult patients with chronic low back pain and related d...

Enrolling
Lumbar Degenerative Disc Disease
Drug: SB-01 For Injection
Drug: Sham Needle

The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-Co...

Enrolling
SARS-CoV-2 Infection
Drug: Placebo
Drug: S-217622

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholester...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Dyslipidemias
Drug: Obicetrapib
Drug: Placebo

This is a 2-part, 2-arm, Phase 2 , multicentre, randomized, double-blind, placebo-controlled study in adults with COVID-19 with gastrointestinal infe...

Active, not recruiting
Covid19
Drug: Placebo
Drug: Niclosamide

The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated...

Active, not recruiting
Colorectal Cancer (CRC)
Drug: Regorafenib
Drug: Panitumumab

Trial sponsors

Pfizer logo
J
Kowa logo
N
NovoCure logo
Amgen logo
AstraZeneca logo
Bavarian Nordic logo
Bristol-Myers Squibb (BMS) logo
E

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems